Characterization of an immunodominant antigenic epitope from Trypanosoma cruzi as a biomarker of chronic Chagas' disease pathology by Thomas, María del Carmen et al.
Characterization of an Immunodominant Antigenic Epitope from
Trypanosoma cruzi as a Biomarker of Chronic Chagas’
Disease Pathology
M. Carmen Thomas,a Ana Fernández-Villegas,a Bartolomé Carrilero,b Concepción Marañón,a Daniel Saura,c Oscar Noya,d
Manuel Segovia,b Belkisyolé Alarcón de Noya,d Carlos Alonso,e and Manuel Carlos Lópeza
Instituto de Parasitología y Biomedicina López Neyra, CSIC, Parque Tecnológico de Ciencias de la Salud, Granada, Spaina; Hospital Virgen de la Arrixaca, Unidad Regional
de Medicina Tropical,b and Servicio de Cardiología,c El Palmar, Murcia, Spain; Biohelmintiasis and Inmunología Laboratories Instituto de Medicina Tropical, Universidad
Central de Venezuela, Caracas, Venezuelad; and Centro de Biología Molecular Severo Ochoa, CSIC-Universidad Autónoma de Madrid, Cantoblanco, Madrid, Spaine
Nowadays, the techniques available for chronic Chagas’ disease diagnosis are very sensitive; however, they do not allow discrimi-
nation of the patient’s clinical stages of the disease. The present paper describes that three out of the five different repeats con-
tained in the Trypanosoma cruzi TcCA-2 membrane protein (3972-FGQAAAGDKPPP, 6303-FGQAAAGDKPAP, and 3973-FGQ
AAAGDKPSL) are recognized with high sensitivity (>90%) by sera from chronic Chagas’ disease patients and that they are not
recognized by sera from patients in the acute phase of the disease. A total of 133 serum samples from chagasic patients and 50
serum samples from healthy donors were tested. In addition, sera from 15 patients with different autoimmune diseases, 43 se-
rum samples from patients suffering an infectious disease other than Chagas’ disease, and 38 serum samples from patients with
nonchagasic cardiac disorders were also included in this study. The residue 3973 peptide shows a specificity of>98%, as it is not
recognized by individuals with autoimmune and inflammatory processes or by patients with a nonchagasic cardiomyopathy.
Remarkably, the levels of antibody against the 3973 epitope detected by the sera from Chagas’ disease patients in the symptom-
atic chronic phase, involving cardiac or digestive alterations, are higher than those detected by the sera from Chagas’ disease pa-
tients in the indeterminate phase of the disease. It is suggested that the diagnostic technique described could also be used to indi-
cate the degree of pathology. The amino acids F, Q, and DKP located in the peptide at positions 1, 3, and 8 to 10, respectively, are
essential to conform to the immunodominant antigenic epitope.
Chagas’ disease (ChD) is caused by the protozoan parasiteTrypanosoma cruzi, which is transmitted by hematophagous
Reduviidae vectors and infects many wild animal reservoirs. De-
spite the intensive programs implemented to control the illness-
transmitting vectors, this neglected tropical sickness affects about
8 million people located in the poorest regions of developing
countries in Latin America and the Caribbean (31, 32). In these
areas, there is a high level of exposure and transmission due to the
poor housing and living conditions, together with ecological fac-
tors that have led to the adaptation of the triatomine vectors. In
addition to congenital transmission, blood transfusion, and organ
transplantations, there are other ways of infection, such as oral
transmission through ingestion of contaminated food, currently
considered an important route of transmission (2). Due to the
increase of immigrants, high numbers of imported ChD cases are
now being detected in areas where the disease is not endemic (18,
24). Therefore, ChD is acquiring relevance from a public health
point of view both in countries where the disease is endemic and in
countries where it is not endemic, where children and pregnant
women are the most vulnerable populations (23).
The disease courses with different clinical forms. The acute
phase appears shortly after infection. In this phase, the parasite
can be visualized in the bloodstream. In the absence of treatment,
the acute phase is followed by an indeterminate stage in which the
parasites persist in specific tissues (28). In about one-third of these
individuals, the infection leads to a symptomatic chronic phase,
characterized by cardiac and digestive involvement (8, 28). Car-
diac manifestations of the disease include arrhythmias, electrocar-
diographic abnormalities, cardiomegaly, and/or systolic dysfunc-
tion (29, 30). Digestive manifestations of the disease include
aperistalsis megaesophagus and megacolon. Although these clin-
ical manifestations are usually not highly severe, they are associ-
ated with morbidity (27).
Nowadays, ChD is diagnosed mostly by serological tests. These
tests are based on the detection of specific antibodies against ho-
mogenates of the parasite’s total proteins or combinations of re-
combinant proteins as antigens. Although these techniques are
very sensitive, they do not allow differentiation of the clinical
phases of the disease. Moreover, these techniques do not seem to
be reliable tools for monitoring the evolution of the disease in
patients after treatment (3, 5, 26, 37). In this context, potential
biomarkers for therapeutic efficacy have recently been described
(9, 38). Detection of the parasite in the bloodstream of treated
patients by PCR does not allow prediction of treatment success,
since even repeated negative PCR results do not necessarily indi-
cate parasitological cure (31). However, diagnosis by PCR may
constitute a tool to highlight the impact of treatment and the
reduction of the parasitic load (25).
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In the T. cruzi parasite, a significant number of proteins con-
taining large tandem repeat domains have been shown to have
significant immunological relevance, since most of them are anti-
genic molecules (12). The antigens bearing amino acid tandem
repeats seem to possess a significant degree of antigenicity and to
be targets of B-cell responses. It seems that the reactivity of cha-
gasic patients’ serum samples against these antigens has a great
degree of specificity and sensitivity (10, 15, 36). It has been de-
scribed that the immunodominant membrane protein of T. cruzi
TcCA-2 bearing different repeated epitopes of 12-mer in length
(4), as well as its homologs, the T-cell receptor 39 (TCR39) (15)
and B13 antigens (13, 15), is recognized with high sensitivity by
sera from ChD patients (1, 7). The TcCA-2 protein also contains
the TcMe (T. cruzi specific epitope) motif, which has been de-
scribed to be involved in the internalization of the parasite into the
host cell (22a). The B13 protein contains T-cell epitopes located in
a tandemly repetitive fashion and has low homology with multiple
epitopes contained in the human cardiac myosin (1, 17). The in-
volvement of cross-reactivity between cardiac myosin and B13 in
the pathogenesis of chronic cardiac ChD has been suggested (6,
17).
The aim of this work was to analyze the reactivity of sera from
chagasic patients against the different repeated epitopes present in
the TcCA-2 protein. The level of recognition of the most immu-
nodominant repetitive epitope, epitope 3973 (FGQAAAGDKP
SL), from TcCA-2 by sera from adult ChD patients having differ-
ent clinical forms of the disease is described. The existence of a
differential reactivity against the 3973 peptide of sera from symp-
tomatic and nonsymptomatic Chagas’ disease patients is also
demonstrated. Furthermore, we have identified the minimal res-
idues that conform to the antigenic epitope.
MATERIALS AND METHODS
Human sera. Following WHO criteria, ChD diagnosis was determined
using two different commercial serological tests (enzyme-linked immu-
nosorbent assay [ELISA; Bioelisa Chagas; Biokit, Barcelona, Spain] and
indirect immunofluorescence assay [IFI; Inmunofluor Chagas; Biocientí-
fica, Argentina]). According to diagnostic test results, a total of 133 serum
samples from chagasic patients and 50 serum samples from healthy do-
nors (HDs) were assayed. Thus, serum samples from 87 chronic ChD
adult patients (Chronic Ch) and 30 control serum samples from healthy
adult donors were collected at the Virgen de la Arrixaca Hospital (Murcia,
Spain). These people came from areas of endemicity and were residents of
Spain, where T. cruzi reinfection does not occur (Table 1). Patients were
considered to be at the indeterminate phase (IND;n 28) when they were
seropositive with no evidence of cardiac disorder (following clinical cri-
teria and radiological, electrocardiographic, and transthoracic echocardi-
ography analyses) or gastrointestinal tract disorder. Patients with chronic
Chagas’ cardiomyopathy (CCC; n 38) were catalogued into stages G1 to
G3, following the Kuschnir classification, according to clinical criteria and
radiological, electrocardiographic, and transthoracic echocardiography
analyses (19). The digestive form (DIG; n  21) was identified when
megaesophagus and/or megacolon abnormalities in the gastrointestinal
track were detected by esophagogram and barium enema analyses. Serum
samples from 11 patients with orally acquired acute ChD (Acute Ch), 35
adults with chronic ChD diagnosed by ELISA (IgG and IgM) and indirect
hemagglutination tests, and 20 healthy donors who live in the area of
endemicity were collected at the Instituto de Medicina Tropical (Caracas,
Venezuela).
Serum samples from patients with different autoimmune disorders or
patients suffering an infectious disease other than the Chagas’ disease were
also included in this study as controls. Thus, sera from 15 patients from
areas of nonendemicity suffering autoimmune diseases (systemic lupus
erythematosus [SLE; n  6], celiac disease [n  4], and rheumatoid ar-
thritis [Ai; n 5]) were collected at the Hospital de la Santa Creu i Sant
Pau (Barcelona, Spain), and 43 serum samples from patients with an
infectious pathology (leishmaniasis [Leish; n 21], tuberculosis [Tuberc;
n  11], and malaria [n  11]) were collected from the Centro para
Estudios sobre Malaria-IAES-MPPS (Caracas, Venezuela). In addition,
serum samples from patients with nonchagasic cardiac disorders
(NChCard; n  38), including dilated idiopathic cardiomyopathy (n 
13), ischemic cardiomyopathy (n 8), valvular cardiomyopathy (n 7),
heart failure with normal left ventricular ejection fraction (n 6), heart
transplantation graft acute rejection (n 2), evolving myocardial infarc-
tion (n  1), and acute viral myocarditis (n  1), were included in this
study.
Ethical considerations. The protocols were approved by the ethical
committees of the Instituto de Medicina Tropical (Caracas, Venezuela)
and Hospital Virgen de la Arrixaca and Consejo Superior de Investigacio-
nes Científicas (Spain). A signed informed consent was obtained from all
individuals prior to their inclusion in the study.
Synthetic peptides. Peptides were synthesized by the simultaneous
multiple-peptide solid-phase method. The peptides were assembled using
the standard tert-butoxycarbonyl (tBoc) solid-phase peptide synthesis
(SPPS) strategy on p-methylbenzhydrylamide (MBHA) resin. Purity was
checked by high-performance liquid chromatography (HPLC), and the
correct composition was verified by mass spectrometry (16). The peptides
used in this study are listed below: 3972 (FGQAAAGDKPPP), 6303 (FG
QAAAGDKPAP), 3973 (FGQAAAGDKPSL), 3963 (FGQAAAGDKLSL),
6173 (FGQAAAGGKPSL), 6175 (AGQAAAGDKPSL), 6380 (FAQAAAG
DKPSL), 6383 (FGAAAAGDKPSL), 3964 (FGQAAAGHKPAP), 3965 (F
GQAAEGDKPPP), 3966 (FGQAAAADKPSL), 3974 (FGQAAAGDLP
SP), 6174 (FGQAAAGDGPSL), 6382 (AAQAAAGDKPSL), 6304 (FAQA
AAADKPSL), 6172 (FGQAAAGERPSL), 6381 (AAAAAAGDKPAA),
6302 (FAQAAAADKPAA), 6385 (QAAAGDKPSLFG), and 6384 (AAGD
KPSLFGQA).
ELISA measurement. The ELISA described here is a modification of a
method described in detail by Thomas et al. (35). Briefly, ELISA 8-well
strips (Nunc-Immuno module F16; Roskilde, Denmark) were coated with
100 l of peptide (10 g/ml in phosphate-buffered saline [PBS]) and
dried stored at20°C until use.
Subsequently, the wells were washed twice with 200 l of PBS– 0.05%
Tween 20 (Sigma) and incubated for half an hour with blocking solution
(2.5% nonfat dried milk powder in PBS). Afterward, patient sera at 1/400,
1/800, and 1/1,600 dilutions were added to the antigen-coated wells and
TABLE 1 Characteristics of the population under study that came from areas of endemicity and that are Spanish residents
Subject groupa Mean (range) age (yr) No. (%) of males/females No. (%) of patients, origin
HD (n 30) 30.6 (24–50) 6 (20.7)/23 (79.3) 26 (86.6), Bolivia; 4 (13.3), Ecuador
IND (n 28) 31.5 (12–47) 8 (28.6)/20 (71.4) 27 (96.4), Bolivia; 1 (3.6), Paraguay
CCC (n 38) 40.0 (28–74) 16 (42.1)/22 (57.9) 38 (100.0), Bolivia
DIG (n 21) 33.7 (12–54) 8 (38.0)/13 (62.0) 21 (100.0), Bolivia
a HD, healthy donors; IND, chronic Chagas’ disease patients at the indeterminate clinical phase of the disease; CCC, chronic cardiac Chagas’ disease patients; DIG, chronic Chagas’
disease patients with abnormalities in the gastrointestinal tract.
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the reaction mixture was incubated for 1 h at 37°C. As a secondary anti-
body, affinity-isolated goat anti-human IgG antibody, peroxidase conju-
gated (Biosource, Spring Valley, NY), was used at a dilution of 1:2,000.
The reaction mixture was incubated for 1 h at 37°C. After the reaction
mixture was washed, the reaction was developed using 3,3=,5,5=-
tetramethylbenzidine (TMB; 0.4 g/liter) and hydrogen peroxide (0.02%)
(1:1) for 10 min at room temperature. The absorbance was measured at
620 nm. Serum samples were assayed in triplicate. Hyperimmune sera
from mice immunized with each peptide coupled to keyhole limpet
hemocyanin (KLH; Sigma) and sera from a healthy donor were included
in all plates as positive- and negative-control sera, respectively.
Statistical analysis. The Mann-Whitney U test was used to carry out
comparisons among groups of patients. Pearson correlation analyses were
used to evaluate the correlation among levels of antibody against the 3973
peptide and 6302 peptide. The relation between level of antibody against
the 3973 peptide and Kuschnir stage was tested with the Jonckheere-
Terpstra statistic on trend. Statistical significance was assigned at a two-
sided P value of0.05. Statistical analyses were performed using the SPPS
statistical package, version 15.0 (SPSS Inc., Chicago IL).
RESULTS
Antigenicity and sensitivity of natural peptides contained in
TcCA-2 antigen. The reactivity of sera from 35 Latin American
residents at the chronic phase of ChD against a series of peptides
that correspond to different 12-mer tandem repeats present in the
TcCA-2 immunodominant antigen of T. cruzi (GenBank acces-
sion number EAN97076) was analyzed. These tandem repeats dif-
fer in their amino acid compositions, affecting 1 or 2 amino acids
located at position 8, 10, 11, or 12 of the repeat. The number of
repeats ranges from 2 to 11. Thus, five peptides of 12 amino acids
in length that correspond to these repeats were synthesized. As
shown in Fig. 1, peptides 3972, 6303, and 3973 are recognized by at
least 90% of chagasic patient sera. Sequence divergences among
these three natural peptides are on positions 11 and 12. Peptide
6303 differs from peptide 3972 in the amino acid located at posi-
tion 11, as it bears alanine instead of proline. Peptide 3973 bears
serine and leucine amino acids at positions 11 and 12 instead of
the prolines in peptide 3972.
A single amino acid divergence in another position of the re-
peat resulted in an important reduction of the percentage of pa-
tients’ sera that recognized the peptide. Thus, peptide 3963 was
recognized by only 30% of the chronic chagasic sera. This drop in
the percentage of patients’ sera that recognized the peptide is due
to the difference in amino acid composition at position 10, as
peptide 3963 bears lysine instead of proline in peptides 3972, 6303,
and 3973. A drastic decrease in the percent recognition was de-
tected when peptide 6173 was tested. This peptide contains a sin-
gle modification that affects position 8 of the repeat. Peptide 6173,
which bears glycine instead of aspartic acid, was recognized by
only 5% of the serum samples. These data indicate that small
differences in the amino acid composition of the repeats strongly
influence the antigenic nature of these sequences. The highest re-
activity was detected when the repeat present in peptide 3973 was
tested (Fig. 1). Consequently, the 3973 peptide was selected for
further studies.
Specificity against 3973 peptide and correlation of serum re-
activity with sickness severity. The reactivity of a larger number
of serum samples from chagasic patients against the 3973 peptide
was analyzed. It was also determined whether the reactivity against
the 3973 peptide is correlated with the disease form and the car-
diac severity phase and whether 3973-specific antibodies are pres-
ent in the sera from patients with other T. cruzi-related infectious
diseases and with other related pathologies. Sera from 87 chronic
ChD adult patients and 30 control serum samples from healthy
adult donors from areas of endemicity (at present, Spanish resi-
dents) were assayed for reactivity against peptide 3973. Sera from
11 patients at the orally acquired acute phase that were collected at
the Instituto de Medicina Tropical (Caracas, Venezuela) were also
assayed for reactivity against the same peptide. The results show
that most chronic ChD patients (94.25%) had antibodies against
the 3973 epitope and that in most of them the reactivity was high
(Fig. 2A). However, the sera from the above-mentioned patients
at the acute phase did not recognize the 3973 peptide (Fig. 2A), an
indication that the presence of anti-3973 antibodies is directly
correlated with the establishment of the chronic pathology. The
high level of specificity (98%) of recognition of peptide 3973 by
the sera from chagasic patients at the chronic phase was clearly
shown by the observation that none of the sera from patients with
leishmaniasis (n  21), tuberculosis (n  11), and malaria (n 
11) recognized this peptide (Fig. 2A).
To address the question whether the anti-3973 reactivity could
correlate with the different phases of the sickness in terms of the
pathology severity, the presence of antibodies in patients present-
ing different clinical forms of the disease was evaluated. Thus, sera
from patients at the indeterminate phase (IND; n 28) and from
patients at the chronic phase who presented chronic cardiac dam-
FIG 1 Reactivity of sera from Chagas’ disease patients against five 12-mer peptides present in the T. cruzi TcCA-2 protein. The amino acid divergences of the
different peptides representing the most abundant repeat are underlined. Data are expressed in optical density (O.D.) values. The horizontal bars represent the
median optical density values and standard deviations obtained against 35 sera from chagasic patients () and 20 serum samples from healthy donors ().
Statistically significant differences (P 0.05) are indicated. Sera were assayed at a 1:400 dilution.
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age (CCC; n  38) or digestive alterations (DIG; n  21) were
analyzed by ELISA. The data indicate that the reactivity against
peptide 3973 detected in the sera from patients with ChD in the
chronic form (both DIG and CCC) is higher, with statistical sig-
nificance, than that detected in sera from patients with the IND
form (Fig. 2B). No statistically significant differences were ob-
served when the reactivity against 3973 in DIG patients was com-
pared to that in CCC patients. There was no correlation between
the patients’ age and the level of reactivity against the 3973 peptide
(data not shown).
In order to rule out the possibility that the recognition of the
3973 epitope is due to other clinical manifestations of cardiac
damage or inflammatory processes not associated with ChD, sera
from patients with cardiomyopathy or other heart disorders
(NchCard) and sera from patients with autoimmune pathologies
such as SLE, celiac disease, and rheumatoid arthritis (Ai; n 15)
were assayed for reactivity against peptide 3973. As shown in Fig.
2B, the reactivity against 3973 is significantly higher in the sera
from chagasic patients having clinical cardiac or digestive mani-
festations than in the sera from patients with nonchagasic cardiac
disorders and patients having autoimmune and inflammatory
processes such as SLE, rheumatoid arthritis, or celiac disease. In
addition, we found a positive trend (P  0.01, Jonckheere-
Terpstra test) in the relation between the reactivity against peptide
3973 by chronic ChD patient sera and the severity of the cardiac
damage determined by the Kuschnir classification value (G0 to
G2/G3) or the presence of digestive disorders (P 0.001) (Fig. 3).
Thus, the data presented suggest that the detection of antibodies
against the T. cruzi 3973 peptide in sera from chronic chagasic
patients may well be used as a serological marker for follow-up of
the evolution of the disease from an asymptomatic stage to a car-
diac or digestive symptomatic form, thus having a prognosis
value.
Identification of amino acid composition and localization of
the epitope contained in the 3973 peptide that is recognized by
sera from chagasic patients. To identify the position and nature
of the amino acids present in the 3973 epitope to which the anti-
bodies are directed, a series of peptides bearing amino acid substi-
tutions along the sequence was synthesized and assayed by ELISA.
Simple, double, and multiple modifications (comprising up to 4
amino acid substitutions) were included in the amino acid se-
quences of peptide 3973 tested. The presence of specific antibodies
in the sera from 35 chronic chagasic patients living in Latin Amer-
ica was determined. The results show (Fig. 4) a drastic reduction in
the recognition level when the 1st, 3rd, 8th, 9th, and 10th positions
were mutated in the repeat, as the sensitivities dropped to less than
50% (6175 peptide), 20% (3964 peptide), 10% (6383, 3974, 6174,
and 6382 peptides), and 5% (6172, 6381, 6385, and 6384 pep-
tides). However, modification of amino acids located at positions
FIG 2 Specificity of IgG antibodies against 3973 peptide. The IgG reactivity against the 3973 peptide was measured by ELISA. Data are expressed as the optical
density (O.D.). Horizontal lines on each group represent the median and interquartile range. Statistically significant differences (P 0.05) are indicated. (A) Sera
from 30 healthy donors (HD, Œ), 11 acute Chagas’ disease patients (Acute Ch, M), 87 chronic Chagas’ disease patients (Chronic Ch, ●), 21 leishmaniasis patients
(Leish, o), 11 tuberculosis patients (Tuberc, ), and 11 malaria patients (). The sera were assayed at 1:800 dilution. (B) Sera from 28 patients with the
indeterminate form (IND, ‘), 21 patients with the digestive form (DIG,), 38 patients with the cardiac form (CCC, ), 38 patients with nonchagasic cardiac
disorders (NChCard,o), and 15 patients with autoimmune disorders (rheumatoid arthritis [Ai], M). Sera were assayed at 1:1,600 dilution.
FIG 3 Correlation analysis by Jonckheere-Terpstra test. The level of IgG-
specific antibodies against the 3973 peptide in sera from 28 patients with the
indeterminate form, 12 patients with the early cardiac form (G1), 26 patients
with advanced cardiac form (G2-G3), and 21 patients with the digestive form
were measured by ELISA. The antibody levels were correlated with clinical
forms by the Jonckheere-Terpstra test. Statistically significant differences (P
0.05) are indicated and marked with an asterisk. The lower and upper limits of
the box indicate the 25th and 75th percentiles, respectively, the line within the
box depicts the median, and the whiskers indicate the lower and upper adja-
cent values.
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2 (peptide 6380), 6 (peptide 3965), and 7 (peptide 3966), includ-
ing double mutations at positions 2 and 7 (peptide 6304), did not
affect the level of recognition, as they were recognized by at least
90% of the ChD patients’ sera. Peptide 6380 revealed the highest
(optical density) reactivity of all the different peptides assayed. All
these peptides share the amino acids phenylalanine (F) at the 1st
position, glutamine (Q) at the 3rd position, aspartic acid (D) at
the 8th position, lysine (K) at the 9th position, and proline (P) at
the 10th position. The relevance of these amino acids at these
particular positions was confirmed by synthesizing a peptide that
maintains invariable the amino acids at positions 1, 8, 9, and 10 in
peptide 3973 and bears alanine at the other positions. The pattern
of recognition of peptide 6302 was similar to that of 3973 as an
indication that the consensus sequence FXQXXXXDKPXX de-
fines the minimal sequence structure required for a proper recog-
nition. More than 90% of the sera recognized peptide 6302.
In order to determine whether there is any correlation between
the reactivity detected against peptides 3973 and 6302, a paired
correlation analysis was carried out. The results shown in Table 2
indicate the existence of a statistically significant correlation in the
recognition of these peptides, with values of r of 0.691 (P 0.001)
for chagasic patients, 0.568 (P  0.005) for patients with cardiac
clinical manifestations, and 0.578 (P  0.001) for patients with
digestive clinical manifestations.
DISCUSSION
Several serological methods for diagnosis of ChD have been de-
veloped and are being used across the world, as they have proven
high rates of sensitivity ranging from 88 to 100% and specificity
near 95% (26). The cross-reactivity of the mentioned methods is
mainly due to the recognition of shared antigens present in Leish-
mania and Trypanosoma rangeli parasites (5). Given that a few
infected patients do not seem to be properly diagnosed, WHO
recommends that the diagnosis be made using two serological
tests and positive results by the two tests be considered evidence of
infection (11, 31). Many antigens of Trypanosoma cruzi that con-
tain highly repetitive immunogenic amino acid motifs have been
used in diagnostic tests for Chagas’ disease. These repetitive motifs
provide markedly improved specificity compared to that obtained
using conventional tests (14). In the study described in the present
paper, we analyzed the reactivity of sera from Chagas’ disease pa-
tients at different clinical phases of the disease against five 12-mer
peptides that correspond to different tandem repeats from the
TcCA-2 immunodominant antigen of T. cruzi (4). The data pre-
sented show that three out of the five different repeats contained
in a TcCA-2 membrane surface protein, peptide 3972 (sequence,
FGQAAAGDKPPP), peptide 6303 (sequence, FGQAAAGDKP
AP), and peptide 3973 (sequence, FGQAAAGDKPSL), are recog-
nized with high sensitivity (90%) by sera from symptomatic and
nonsymptomatic chronic ChD patients. These peptides are not
recognized by sera from patients in the orally acquired acute phase
of the disease.
The level of recognition detected against each one of the as-
sayed repeats is not related to the abundance of the epitopes in the
TcCA-2 protein (GenBank accession number EAN97076), since
the highest level of reactivity is directed against the 3973 epitope,
which is the least represented repeat in the protein (2 repeats). A
similar recognition level was observed with sera from different
regions where ChD is endemic (laboratory data). It has been de-
scribed that the homologous tandemly repetitive sequences pres-
ent in the B13 antigen fromT. cruzi (Y strain) can be presented for
T-cell recognition in the context of at least three distinct HLA class
FIG 4 Identification of minimal residues that conform to the antigenic epitope recognized by the chagasic patients’ serum samples. Reactivity of sera from
Chagas’ disease patients against 15 12-mer-long peptides derived from the 3973 peptide contained in the protein TcCA-2. Mutated positions are underlined. The
horizontal bars represent the median values with interquartile range of 35 serum samples from chagasic patients () and 20 serum samples from healthy donors
(). Data are expressed in optical density (O.D.) values. Statistically significant differences (P 0.05) are indicated.
TABLE 2 Correlation between the reactivity of sera against peptides
3973 and 6302
Subject groupa
Correlation for 3973 vs 6302
P value r
Chagasic patients 0.001 0.691
IND 0.001 0.556
CCC 0.005 0.568
DIG 0.001 0.578
a IND, chronic Chagas’ disease patients with indeterminate clinical form of the disease;
CCC, chronic cardiac Chagas’ disease patients; DIG, chronic Chagas’ disease patients
with abnormalities in the gastrointestinal tract.
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II molecules (1). Furthermore, our results also show that a single
amino acid divergence in a particular position of the repeat (P in
position 10 replaced by L or D in position 8 replaced by G) resulted
in a dramatic reduction of the percentage of patients’ sera that
recognized the peptide, an indication of the essential role that
certain amino acids may play in the conformation of the immu-
nodominant antigenic epitope. Moreover, a dramatic reduction
in the recognition level was also detected when the amino acids F,
Q, and K at the first, third, and ninth positions were mutated in
peptide 3973. However, amino acid substitution at positions 2 (G
replaced by A), 6 (A replaced by E), 7 (G replaced by A), 11 (S
replaced by P or A), and 12 (L replaced by P or A) are irrelevant in
terms of the recognition level.
The 3973 epitope does not cross-react with sera from patients
with leishmaniasis and other related infectious diseases, showing a
degree of specificity higher than 98% when tested against the sera
from ChD patients. Moreover, the level of recognition of the 3973
peptide by sera from patients at the symptomatic chronic phase
involving cardiac or digestive alterations is higher (P  0.01 and
P  0.005, respectively) than that by sera from patients at the
indeterminate phase of the disease. The data presented here also
show that the 3973 epitope is not recognized by the sera from
individuals with SLE, rheumatoid arthritis, or celiac disease or
patients with a nonchagasic cardiomyopathy. The results suggest
the presence of the parasite in tissues from chronic ChD patients
and its essential role in the pathogenesis of the chronic phase of
this disease (20, 28, 33).
The higher level of 3973 epitope-specific antibodies observed
in sera from symptomatic chronic ChD patients than in sera from
asymptomatic patients may be associated with parasite prolifera-
tion in the infected tissues due to a breaking off of the fragile
equilibrium between the host immune response and the prolifer-
ation of parasites in patients at the indeterminate phase of the
disease. In fact, an association between the parasite load and sick-
ness severity has been described (22). However, the possibility
cannot be excluded that during the infection the mimicry of par-
asite antigens with host self-antigens might lead to immune con-
fusion and activation of the response against particular antigenic
epitopes of the parasite. Supporting this assumption, it has been
described that CD4 T-cell clones that infiltrated the hearts of
CCC patients cross-recognize human cardiac myosin and the T.
cruzi B13 protein (17).
We believe that regardless of the cause of the variation in reac-
tivity against the 3973 peptide during instauration and progres-
sion of chronic ChD, the results described here have an important
value for the follow-up of patients with this disease and for the
evaluation of tissue damage progression. In fact, a positive trend
(Jonckheere-Terpstra test) was found between the level of reactiv-
ity against the 3973 peptide in sera from chronic ChD patients and
the severity of the cardiac damage determined by the Kuschnir
classification (G0 to G2/G3), as well as between patients with di-
gestive alterations of ChD and patients at the indeterminate phase.
Thus, the diagnostic technique described has demonstrated high
sensitivity and specificity, and its results can correlate with the
degree of pathology of chronic ChD and define when a ChD pa-
tient in the indeterminate phase may progress toward a phase with
cardiopathy or digestive disorders. Currently, the treatment with
benznidazole or nifurtimox has been shown to be effective in pa-
tients at the acute phase of the disease, but its efficacy in adult
patients at the chronic phase is under consideration (21, 39).
There is a pressing need for useful tools that may discriminate
between different grades of disease severity to help the clinician to
decide whether or not to treat a particular chronic ChD patient
and to make a favorable posttreatment follow-up.
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